Subscribe
shutterstock_1757758247_oasis2me
oasis2me / Shutterstock.com
8 March 2022BiotechnologyTakanori Abe

Will authorised biologics deter biosimilars? Utilising JFTC’s expertise in drug pricing

Issue: Report of the Japan Biosimilar Association

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Japan’s IP office upholds CRISPR patent and allows third
1 June 2021   A CRISPR patent filed by scientist Emmanuelle Charpentier alongside the Regents of the University of California and the University of Vienna has been upheld by the Japan Patent Office.
Big Pharma
Chiesi blocks Japanese drugmaker’s new brand at EU General Court
1 July 2020   Japan-based Nitto Pharmaceutical Industries has been blocked from using its ‘Noster’ brand in the EU, in a win for Italian drugmaker Chiesi Farmaceutici.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Biotechnology
Japan’s IP office upholds CRISPR patent and allows third
1 June 2021   A CRISPR patent filed by scientist Emmanuelle Charpentier alongside the Regents of the University of California and the University of Vienna has been upheld by the Japan Patent Office.
Big Pharma
Chiesi blocks Japanese drugmaker’s new brand at EU General Court
1 July 2020   Japan-based Nitto Pharmaceutical Industries has been blocked from using its ‘Noster’ brand in the EU, in a win for Italian drugmaker Chiesi Farmaceutici.

More on this story

Biotechnology
Japan’s IP office upholds CRISPR patent and allows third
1 June 2021   A CRISPR patent filed by scientist Emmanuelle Charpentier alongside the Regents of the University of California and the University of Vienna has been upheld by the Japan Patent Office.
Big Pharma
Chiesi blocks Japanese drugmaker’s new brand at EU General Court
1 July 2020   Japan-based Nitto Pharmaceutical Industries has been blocked from using its ‘Noster’ brand in the EU, in a win for Italian drugmaker Chiesi Farmaceutici.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
CREATES Act unfairly tips the scales to generics
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
Judge denies Intellia bid to throw out suit over $100m Regeneron pact
Trump’s return sparks calls for pro-patent agenda
Amgen faces pushback over bid to narrow patent scope